Sozinibercept is under clinical development by Opthea and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Sozinibercept’s likelihood of approval (LoA) and phase transition for Wet (Neovascular / Exudative) Macular Degeneration took place on 04 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sozinibercept Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Sozinibercept overview

OPT-302 (VGX-300) is under development for the treatment of wet age-related macular degeneration and diabetic macular edema. The drug candidate is administered through the intravitreal route. It is a soluble fusion protein comprising of vascular endothelial growth factor receptor 3 (VEGFR-3) fused to the Fc fragment of human immunoglobulin G1 (IgG1). The drug candidate acts by targeting vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). It was also under development for the treatment of solid tumors.

Opthea overview

Opthea formerly Circadian Technologies, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vascular endothelial growth factors. Its pipeline products include VEGF-C, VEGF-D and VEGFR-3. Opthea’s lead compound, OPT-302 is used in combination with existing VEGF-A inhibitors in patients with age-related macular degeneration and diabetic macular edema. The company’s VEGF-D diagnostics is a prognostic indicator of number of tumor types, and VEGF-C diagnostics, an indicator of survival rate. It partners with healthcare and diagnostic centers. Circadian is headquartered in Melbourne, Victoria, Australia.

Quick View Sozinibercept LOA Data

Report Segments
  • Innovator
Drug Name
  • Sozinibercept
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Developers
  • Sponsor Company: Opthea
  • Originator: Vegenics
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.